Heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
== Leadership == Phil Keiser became the second CEO of the franchise in June 2015 until his death in October 2016. Joe Koss followed him in January 2017 until retiring at the end of 2020. He was succeeded by Enrique "Rick" Silva in March 2021. Silva retired in April 2025 and was replaced with Julie Fussner, the first female CEO of the company. She was previously the chief marketing officer, and had been with the company since 2017.
acquired bowel herniation (this becomes a risk for larger donor sites (>4 cm)). About 20 cases have been reported in the literature from 1945 until 1989 and only a few hundred cases have been reported worldwide meralgia paresthetica (injury to the lateral femoral cutaneous nerve also called Bernhardt-Roth's syndrome) pelvic instability fracture (extremely rare and usually with other factors) injury to the clunial nerves (this will cause posterior pelvic pain which is worsened by sitting) injury to the ilioinguinal nerve infection minor hematoma (a common occurrence) deep hematoma requiring surgical intervention seroma ureteral injury pseudoaneurysm of iliac artery (rare) tumor transplantation cosmetic defects (chiefly caused by not preserving the superior pelvic brim) chronic pain Bone grafts harvested from the posterior iliac crest in general have less morbidity, but depending on the type of surgery, may require a flip while the patient is under general anesthesia.
== Awards and honours == 2004 National Science Foundation CAREER Award 2010 American Chemical Society Horace S. Isbell Award 2017 Elected Edward, Frances, and Shirley B. Daniels Fellow at Harvard University 2017 International Fluorous Technology Award 2017 Silicon Valley Chemist Harry and Carol Mosher Award 2018 American Chemical Society Melville L. Wolfram Award 2019 Fulbright Program Scholar 2020 Elected a Fellow of the American Association for the Advancement of Science
Sources: en.wikipedia.org
The term pair bond originated in 1940 in reference to mated pairs of birds; referring to a monogamous or relatively monogamous relationship. Whilst some form of monogamy may characterise around 90% of bird species, in mammals long-term pairing (beyond the brief duration of copulation itself) is rare, at around 3% (see animal monogamy). The incidence of monogamy in primate species is similarly low in contrast with polygyny (one male mating with two or more females), the most common pattern. However, regardless of mating patterns, primate life is typically characterised by long-lasting social relationships (whether sexual, care-giving, coalitionary or otherwise) formed in the context of living in durable social groups, and any such durable relationship (whether exclusive or not) is characterised by some degree of bonding. Similarly, whilst the 'naturalness' of monogamy in humans is debated, durable monogamous or polygamous relationships will typically be accompanied by affectional or emotional bonding (see next section).
An immediate ceasefire. The withdrawal of MNLA and HCUA forces to designated cantonment sites, primarily around Kidal. The deployment of the Malian army to Kidal to secure the elections. The formation of a joint commission, comprising the Malian army, rebel groups, French forces, and the United Nations Multidimensional Integrated Stabilization Mission in Mali (MINUSMA), to oversee the implementation of security measures. The inclusion of the term "Azawad" in the agreement, despite opposition from Bamako. Although the Malian government initially demanded the disarmament of the MNLA, this condition was waived in exchange for the rebels allowing the Malian army back into Kidal. Furthermore, the MNLA and HCUA did not secure an amnesty for their leaders, many of whom remained under international arrest warrants.
=== RNP immunoprecipitation (RIP and CLIP) === RIP and CLIP both purify a specific RNA-binding protein in order to identify bound RNAs, thereby studying ribonucleoproteins (RNPs). In RIP, the co-purified RNAs are extracted and their enrichment is compared to control, which was originally done by microarray or RT-PCR. In CLIP, cells are UV crosslinked prior to lysis, followed by additional purification steps beyond standard immunoprecipitation, including partial RNA fragmentation, high-salt washing, SDS-PAGE separation and membrane transfer, and identification of direct RNA binding sites by cDNA sequencing.
== Arrest and conviction == Archerd was arrested on July 27, 1967, in Los Angeles for a threefold murder. He was convicted of killing the following: Zella Archerd, his fourth wife (July 25, 1956, two months after their wedding); Burney Archerd, his nephew (September 2, 1961, in Long Beach); and Mary Brinker Post, his seventh wife (November 3, 1966). Others suspected to be victims of Archerd are: William Jones Jr. (October 12, 1947, in Fontana), Juanita Plum Archerd, his fifth wife (March 13, 1958, in Las Vegas); and Frank Stewart (March 17, 1960). All exhibited symptoms of hypoglycemia. Archerd was sentenced to death on March 6, 1968, for three of the murder cases. The medical personnel, law enforcement, and prosecution team were unaware of the availability of an accurate and sensitive assay for blood insulin levels developed years earlier by Rosalyn Yalow in collaboration with Solomon Berson working at the Bronx Veterans Administration Hospital. Instead, they presented some unproven laboratory evidence that, in retrospect, should not have been accepted in court. In December 1970, the death sentence was upheld by the California Supreme Court. In 1972, the sentence was instead changed to life imprisonment after a ruling by the United States Supreme Court. Archerd died of pneumonia in 1977 at the age of 65.
Sources: en.wikipedia.org
Usually, an enzyme molecule has only one active site, and the active site fits with one specific type of substrate. An active site contains a binding site that binds the substrate and orients it for catalysis. The orientation of the substrate and the close proximity between it and the active site is so important that in some cases the enzyme can still function properly even though all other parts are mutated and lose function. Initially, the interaction between the active site and the substrate is non-covalent and transient. There are four important types of interaction that hold the substrate in a defined orientation and form an enzyme-substrate complex (ES complex): hydrogen bonds, van der Waals interactions, hydrophobic interactions and electrostatic force interactions. The charge distribution on the substrate and active site must be complementary, which means all positive and negative charges must be cancelled out. Otherwise, there will be a repulsive force pushing them apart. The active site usually contains non-polar amino acids, although sometimes polar amino acids may also occur. The binding of substrate to the binding site requires at least three contact points in order to achieve stereo-, regio-, and enantioselectivity. For example, alcohol dehydrogenase which catalyses the transfer of a hydride ion from ethanol to NAD+ interacts with the substrate methyl group, hydroxyl group and the pro-(R) hydrogen that will be abstracted during the reaction.
For example, the chemotherapeutic drugs oxaliplatin and cyclophosphamide can cause tumor cells to die in a way that is detectable by the immune system (called immunogenic cell death), which mobilizes immune cells with antitumor functions. Chemotherapeutic drugs that cause cancer immunogenic tumor cell death can make unresponsive tumors sensitive to immune checkpoint therapy.
Important modern products are EPO (Binocrit and NeoRecormon), Enbrel (etanercerpt), Remicade (infliximab), MabThera/Rituxin (rituximab), and Herceptin (trastuzumab). PEGylation is a big step forward regarding administration of peptide and protein drugs. This method offers the two-fold advantage of substituting injection by oral administration and reducing the dosage, and therefore the cost, of the treatment. The pioneer company in this field is Prolong Pharmaceuticals which has developed a PEGylated erythropoietin (PEG-EPO). Oligonucleotides are a third category of big molecules. They are oligomers of nucleotides, which in turn are composed of a five-carbon sugar (either ribose or desoxyribose), a nitrogenous base (either a pyrimidine or a purine) and 1–3 phosphate groups. The best known representative of a nucleotide is the coenzyme ATP (Adenosine triphosphate), MW 507.2. Oligonucleotides are chemically synthesized from protected phosphoramidites of natural or chemically modified nucleosides. The oligonucleotide chain assembly proceeds in the direction from 3'- to 5'-terminus by following a procedure referred to as a "synthetic cycle". Completion of a single synthetic cycle results in the addition of one nucleotide residue to the growing chain. The maximum length of synthetic oligonucleotides hardly exceeds 200 nucleotide components.
== Choanoflagellates == All animals are posited to have evolved from a flagellated eukaryote. Their closest known living relatives are the choanoflagellates, collared flagellates whose cell morphology is similar to the choanocyte cells of certain sponges. Molecular studies place animals in a supergroup called the opisthokonts, which also includes the choanoflagellates, fungi, and a few small parasitic protists. The name comes from the posterior location of the flagellum in motile cells, such as most animal spermatozoa, whereas other eukaryotes tend to have anterior flagella instead.
== Structure == C1q is a 460 kDa protein formed from 18 peptide chains in 3 subunits of 6. Each 6 peptide subunit consists of a Y-shaped pair of triple peptide helices joined at the stem and ending in a globular non-helical head. The 80-amino acid helical component of each triple peptide contain many Gly-X-Y sequences, where X and Y are proline, isoleucine, or hydroxylysine; they, therefore, strongly resemble collagen fibrils.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.